BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33256400)

  • 1.
    Yang T; Hu M; Chen Y; Xiang M; Tang M; Qi W; Shi M; He J; Yuan X; Zhang C; Liu K; Li J; Yang Z; Chen L
    J Med Chem; 2020 Dec; 63(23):14921-14936. PubMed ID: 33256400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
    Yang T; Hu M; Qi W; Yang Z; Tang M; He J; Chen Y; Bai P; Yuan X; Zhang C; Liu K; Lu Y; Xiang M; Chen L
    J Med Chem; 2019 Nov; 62(22):10305-10320. PubMed ID: 31670517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and SARs of 5-Chloro-
    Wang Y; Chen X; Yan Y; Zhu X; Liu M; Liu X
    J Med Chem; 2020 Mar; 63(6):3327-3347. PubMed ID: 32129996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.
    Hanan EJ; van Abbema A; Barrett K; Blair WS; Blaney J; Chang C; Eigenbrot C; Flynn S; Gibbons P; Hurley CA; Kenny JR; Kulagowski J; Lee L; Magnuson SR; Morris C; Murray J; Pastor RM; Rawson T; Siu M; Ultsch M; Zhou A; Sampath D; Lyssikatos JP
    J Med Chem; 2012 Nov; 55(22):10090-107. PubMed ID: 23061660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
    Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
    Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
    Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
    Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.
    Lim J; Taoka B; Otte RD; Spencer K; Dinsmore CJ; Altman MD; Chan G; Rosenstein C; Sharma S; Su HP; Szewczak AA; Xu L; Yin H; Zugay-Murphy J; Marshall CG; Young JR
    J Med Chem; 2011 Oct; 54(20):7334-49. PubMed ID: 21942426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold.
    Yin Y; Chen CJ; Yu RN; Shu L; Zhang TT; Zhang DY
    Bioorg Med Chem; 2019 Apr; 27(8):1562-1576. PubMed ID: 30846405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Discovery of potent and selective JAK2 inhibitors.
    Ioannidis S; Lamb ML; Almeida L; Guan H; Peng B; Bebernitz G; Bell K; Alimzhanov M; Zinda M
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1669-73. PubMed ID: 20144546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.
    Quintás-Cardama A
    Leuk Res; 2013 Apr; 37(4):465-72. PubMed ID: 23313046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors.
    Su Q; Ioannidis S; Chuaqui C; Almeida L; Alimzhanov M; Bebernitz G; Bell K; Block M; Howard T; Huang S; Huszar D; Read JA; Rivard Costa C; Shi J; Su M; Ye M; Zinda M
    J Med Chem; 2014 Jan; 57(1):144-58. PubMed ID: 24359159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2.
    Heightman TD; Berdini V; Bevan L; Buck IM; Carr MG; Courtin A; Coyle JE; Day JEH; East C; Fazal L; Griffiths-Jones CM; Howard S; Kucia-Tran J; Martins V; Muench S; Munck JM; Norton D; O'Reilly M; Palmer N; Pathuri P; Peakman TM; Reader M; Rees DC; Rich SJ; Shah A; Wallis NG; Walton H; Wilsher NE; Woolford AJ; Cooke M; Cousin D; Onions S; Shannon J; Watts J; Murray CW
    J Med Chem; 2021 Aug; 64(16):12286-12303. PubMed ID: 34387469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of
    Tian Y; Qin S; Zhang F; Luo J; He X; Sun Y; Yang T
    ACS Med Chem Lett; 2023 Aug; 14(8):1113-1121. PubMed ID: 37583815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.
    William AD; Lee AC; Blanchard S; Poulsen A; Teo EL; Nagaraj H; Tan E; Chen D; Williams M; Sun ET; Goh KC; Ong WC; Goh SK; Hart S; Jayaraman R; Pasha MK; Ethirajulu K; Wood JM; Dymock BW
    J Med Chem; 2011 Jul; 54(13):4638-58. PubMed ID: 21604762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Thieno[3,2-
    Cho H; Shin I; Yoon H; Jeon E; Lee J; Kim Y; Ryu S; Song C; Kwon NH; Moon Y; Kim S; Kim ND; Choi HG; Sim T
    J Med Chem; 2021 Aug; 64(16):11934-11957. PubMed ID: 34324343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 3,4-Dihydrobenzo[
    Li Y; Zhang L; Yang R; Qiao Z; Wu M; Huang C; Tian C; Luo X; Yang W; Zhang Y; Li L; Yang S
    J Med Chem; 2022 Feb; 65(3):1786-1807. PubMed ID: 34985886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
    Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
    Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.
    Brasca MG; Gnocchi P; Nesi M; Amboldi N; Avanzi N; Bertrand J; Bindi S; Canevari G; Casero D; Ciomei M; Colombo N; Cribioli S; Fachin G; Felder ER; Galvani A; Isacchi A; Motto I; Panzeri A; Donati D
    Bioorg Med Chem; 2015 May; 23(10):2387-407. PubMed ID: 25882525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Pteridine-7(8
    Dou D; Diao Y; Sha W; Su R; Tong L; Li W; Leng L; Xie L; Yu Z; Song H; Shen Z; Zhu L; Zhao Z; Xie H; Chen Z; Li H; Xu Y
    J Med Chem; 2022 Feb; 65(3):2694-2709. PubMed ID: 35099969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.